Company profile
Orphagen Pharmaceuticals, Inc.
Orphagen transforms unexplored biology into clinical-stage innovation in autoimmune disease and oncology.
- Industry
- Biotechnology
- Employees
- 7
- Headquarters
- San Diego, California
- LinkedIn followers
- 1,135
- Office locations
- 1
Orphagen Pharmaceuticals, Inc. company summary
Orphagen Pharmaceuticals, Inc. is a company in the Biotechnology industry, headquartered in San Diego, California. On LinkedIn the company has around 7 employees and 1,135 followers. Its listed specialties include Drug discovery, Pharmaceutical Research, Nuclear Receptors, Pediatric oncology, Rare disease.
What technology does Orphagen Pharmaceuticals, Inc. use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Orphagen Pharmaceuticals, Inc.
Orphagen Pharmaceuticals discovers and develops first-in-class small-molecule therapies targeting orphan nuclear receptors—novel pathways with breakthrough potential in immunology, pediatric rare diseases, and cancer. Orphagen's lead oncology program, OR-449, is a first-in-class breakthrough small molecule for the treatment of a rare and aggressive cancer of the adrenal gland, adrenocortical cancer (ACC), that lacks an effective standard of care. OR-449 is a potent and highly selective antagonist to the orphan nuclear receptor, steroidogenic factor-1 (SF-1 or NR5A1), a cetral transcription factor in the growth and development of ACC. OR-449 is close to IND filing and could receive FDA approval within 5 years for what we estimate is a $1 B global market for ACC. In addition, SF-1 antagonists can be developed as a precision therapy for SF-1(HIGH) head and neck and lung squamous cancers, increasing the treatable patient population for OR-449 several fold. CPRIT, the Texas State Cancer Agency, will contribute a $10.2 M Product Development Award for a Phase 1 trial of OR-449 in adult ACC once appropriate seed funds have been raised. Orphagen’s pipeline also includes a novel candidate for treatment of inflammatory bowel disease (OR-812). Development and translational studies are currently supported by an NIH SBIR grant. OR-812 is an antagonist of retinoic acid receptor alpha (RARA). Blocking RAR-alpha represents a highly differentiated approach to suppression of gut inflammation and is supported by extensive preclinical findings. Based in San Diego, Orphagen is pursuing novel biology to create clinical-stage innovation. For partnership or investor inquiries, contact: info@orphagen.com.
Specialties
Where is Orphagen Pharmaceuticals, Inc. located?
Orphagen Pharmaceuticals, Inc. lists 1 location.
Compare companies similar to Orphagen Pharmaceuticals, Inc.
More companies in Biotechnology.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Orphagen Pharmaceuticals, Inc. orphagen.com | Biotechnology | 7 | - | San Diego, California |
 Regeneron regeneron.com | Biotechnology | 17,234 | - | Tarrytown, New York |
 Bharat Biotech bharatbiotech.com | Biotechnology | 2,035 | 1996 | Hyderabad, Telangana |
 Enzene Biosciences Ltd enzene.com | Biotechnology | 1,023 | 2008 | Pune, Maharashtra |
| Biotechnology | 393 | - | Bethesda, MD | |
 LifeCell International Pvt.Ltd lifecell.in | Biotechnology | 2,650 | 2004 | Chennai, India |
 TMG - Tropical Melhoramento & Genética tmg.agr.br | Biotechnology | 692 | 2001 | Cambé, PR |
 Organica Biotech organicabiotech.com | Biotechnology | 146 | 2000 | Mumbai, Maharashtra |
 Allogene Therapeutics allogene.com | Biotechnology | 217 | 2017 | South San Francisco, California |
 Labtest Diagnóstica S.A. labtest.com.br | Biotechnology | 227 | 1971 | Lagoa Santa, Minas Gerais |
 Orchard Therapeutics - U.S. orchard-tx.com | Biotechnology | 243 | 2015 | London, United Kingdom |
Frequently asked questions about Orphagen Pharmaceuticals, Inc.
What does Orphagen Pharmaceuticals, Inc. do?
Orphagen Pharmaceuticals discovers and develops first-in-class small-molecule therapies targeting orphan nuclear receptors—novel pathways with breakthrough potential in immunology, pediatric rare diseases, and cancer. Orphagen's lead oncology program, OR-449, is a first-in-class breakthrough small molecule for the treatment of a rare and aggressive cancer of the adrenal gland, adrenocortical cancer (ACC), that lacks an effective standard of care. OR-449 is a potent and highly selective antagonist to the orphan nuclear receptor, steroidogenic factor-1 (SF-1 or NR5A1), a cetral transcription factor in the growth and development of ACC. OR-449 is close to IND filing and could receive FDA approval within 5 years for what we estimate is a $1 B global market for ACC. In addition, SF-1 antagonists can be developed as a precision therapy for SF-1(HIGH) head and neck and lung squamous cancers, increasing the treatable patient population for OR-449 several fold. CPRIT, the Texas State Cancer Agency, will contribute a $10.2 M Product Development Award for a Phase 1 trial of OR-449 in adult ACC once appropriate seed funds have been raised. Orphagen’s pipeline also includes a novel candidate for treatment of inflammatory bowel disease (OR-812). Development and translational studies are currently supported by an NIH SBIR grant. OR-812 is an antagonist of retinoic acid receptor alpha (RARA). Blocking RAR-alpha represents a highly differentiated approach to suppression of gut inflammation and is supported by extensive preclinical findings. Based in San Diego, Orphagen is pursuing novel biology to create clinical-stage innovation. For partnership or investor inquiries, contact: info@orphagen.com.
How many employees does Orphagen Pharmaceuticals, Inc. have?
Orphagen Pharmaceuticals, Inc. has around 7 employees on LinkedIn.
Where is Orphagen Pharmaceuticals, Inc. headquartered?
Orphagen Pharmaceuticals, Inc. is headquartered in San Diego, California.
Build a lead list from companies like Orphagen Pharmaceuticals, Inc.
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.